Hypersensitivity PneumonitisNCT02523833
Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis
A study testing Salbutamol in people with Hypersensitivity Pneumonitis and Airway Disease Small, run by University of Sao Paulo General Hospital at 1 site in Brazil.
Trial summary
Hypersensitivity pneumonitis (HP) is a syndrome with variable clinical presentation in which lung inflammation is caused by inhalation of specific organic antigens or low molecular weight particles in previously sensitized individuals. Systemic symptoms may or may not be present. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hypersensitivity Pneumonitis, Airway Disease Small
- What is being tested?
- Salbutamol
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteBrazil
- Study dates
- 1 Sep 2015to 20 Nov 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of chronic hypersensitivity pneumonitis confirmed by:
- patients with known exposure to antigen, tomographic criteria and absence of other diagnoses;
- confirmation with histology obtained by transthoracic biopsy, surgical biopsy or bronchoalveolar lavage with lymphocytosis above 30%;
- Age between 18 to 75 years;
- Clinically stable (no exacerbations or hospitalizations related to the underlying disease) for at least 6 weeks;
- Compliance with signing an informed consent for participation in the project.
Who cannot join
- Patients with FEV1 and / or DLCO <30% predicted;
- Patients using supplemental oxygen;
- Previous diagnosis of asthma or COPD;
- Pregnant women;
- Musculoskeletal disorders that limit exercise;
- Another medical condition that might interfere with the execution of tests;
- Current or past smoking history with tobacco intake greater than 30 pack-years;
- Severe heart disease functional class New York Heart Association (NYHA) III-IV) and / or decompensated hear failure.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis and Its Impact on Exercise Limitation
Hypersensitivity pneumonitis (HP) is a syndrome with variable clinical presentation in which lung inflammation is caused by inhalation of specific organic antigens or low molecular weight particles in previously sensitized individuals. Systemic symptoms may or may not be present. Chronic HP represents the final stage of the disease, caused by prolonged exposure to a particular antigen, leading to pulmonary fibrosis. In chronic HP, pulmonary function tests (PFTs) commonly present a restrictive ventilatory pattern, with decreased diffusion of carbon monoxide (DLCO). Some patients can also have obstructive disorders with expiratory flow limitation, due to obstruction of the small airways typically caused by bronchiolar involvement in this pathology. However, PFTs are relatively insensitive for detecting small airway involvement when there is concomitant interstitial fibrosis. First, conventional PFTs may be normal in patients with small airway involvement, since they contribute to less than 30% of the total airway resistance. In addition, damage to the small airways in HP is generally occurring parallel to areas of focal fibrosis - even when small airways are involved, these regions can be completely ignored, since they are excluded from ventilation. In summary, traditional PFTs are not sufficiently sensitive to detect diffuse small airway involvement in these diseases. In these cases, other functional tests, such as forced oscillation technique (FOT) and high resolution computer tomography (HRCT) scans of the chest with expired studies, could be used for this purpose.
This will be a cross-sectional study, which will include the following evaluations in 28 patients with HP recruited from our clinic:
Read more
- Clinical variables: (A) demographic and anthropometric data; (B) Clinical data: Onset of symptoms and time of diagnosis
- Dyspnea score:
- Smoking: * Current or former smoker * Smoking history (number of cigarettes smoked per day and for how long);
- Spirometry with forced and slow maneuvers before and after bronchodilator (salbutamol);
- Plethysmography to measure lung volumes;
- Diffusion capacity of carbon monoxide (DLCO);
- High-resolution chest CT with expiratory scans;
- Six-minute walk test;
- Cardio-respiratory test using a maximal incremental treadmill.
- Forced oscillation technique (FOT).
Read the detailed description
Hypersensitivity pneumonitis (HP) is a syndrome with variable clinical presentation, in which inflammation in lung parenchyma is caused by inhalation of organic antigens or specific low molecular weight substances in previously sensitized individuals. Systemic symptoms may or not be present. Chronic HP represents the final stage of this disease, where prolonged exposure to a particular antigen would lead to lung fibrosis. The list of new antigens is growing, but the main antigens responsible for this disease are exposure to mold and birds.
Not all exposed individuals develop HP. The pathophysiology involves initial exposure and a subsequent decrease in antigen tolerance. Genetic susceptibility can also modulate the immune response to a specific antigen.
There are no reliable epidemiological data on the incidence or prevalence of HP. Differences in the type of antigen sensitization, lack of standardized diagnostic criteria and underreporting are possible factors. In Mexico, one of the few population surveys showed an estimated incidence of 30 cases per 100000 inhabitants in 2 years (1988-1990); however, there are some bias that limit the extrapolation of data to other contexts.
The patient rarely associates the onset of symptoms with a relevant exposure, making it important to actively search for environmental factors against respiratory complaints. It is believed that intermittent exposure to an antigen, long-term exposure to a small load of antigen or a cumulative effect of multiple episodes of acute exposure can cause chronic HP. It is noteworthy that only a small proportion of patients with a single episode of acute exposure will develop chronic HP.
In chronic HP, the patient complains of dyspnea on exertion and dry cough. Systemic symptoms such as fever and weight loss are rarely reported and may be associated with episodes of acute exposure. Physical examination reveals crackles and less commonly, digital clubbing. Auscultation may reveal the presence of squawks arising from the abrupt opening of small airways. Hypoxemia is found in patients with more severe lung disease.
The differential diagnosis with other fibrosing interstitial diseases is challenging, due to the overlap of clinical history, functional and tomographic findings in the terminal stages of these pathologies. There is no gold standard test for diagnosis of HP in all its forms: the diagnosis results in the combination of epidemiological, clinical, radiological data and other exams.
High resolution computer tomography (HRCT) has a fundamental role in the differential diagnosis. However, in advanced stages, the tomographic scans can demonstrate a pattern indistinguishable from nonspecific interstitial pneumonia (NSIP) or usual interstitial pneumonia (UIP), with presence of architectural distortion, traction bronchiectasis and bronchiolectasis, minimum ground glass opacities and honeycombing. The interpretation of HRCT allows "clues" for the differential diagnosis with other idiopathic intersticial pneumonias (IIPs). In comparative HRCT studies, there were some findings showing small airway involvement, such as lobular areas with decreased attenuation and vascularity, air trapping and ground glass or centrilobular micronodules Surgical biopsy may aid in the differential diagnosis of HP from other chronic idiopathic interstitial pneumonitis, especially when exposure is unclear. Even in advanced fibrosis, the accentuation of inflammation around the small airways is the major finding.
Pulmonary function tests (PFTs) commonly show restrictive ventilatory defect with decreased DLCO. There may be concomitant obstructive ventilatory defect, secondary to involvement of the small airways.
However, PFTs are relatively insensitive for detecting small airway involvement when there is concomitant interstitial fibrosis. Firstly, conventional PFTs may be normal in patients with involvement of small airways since they contribute to less than 30% of total airway resistance. Furthermore, damage to small airways in HP is generally focal occurring in parallel with fibrosed areas - even when small airways are involved, these regions may be completely disregarded since they are excluded from ventilation, with PFTs globally featuring a standard restrictive pattern.
In summary, traditional PFTs are not sensitive enough to detect diffuse small airway involvement in these diseases, no matter how severe it is, neither can detect focal changes. In these cases, the investigators hypothesize that other tests, such as forced oscillometry technique (FOT), with its experience widely recognized in the context of evaluation of obstructive diseases like asthma and chronic obstructive pulmonary disease (COPD) and the technique of negative expiratory pressure (NEP) could be used for this purpose. For now, imaging tests, especially high-resolution tomography with expiratory scans, seem to be more sensitive to detect small airway involvement.
Removal of the causal exposure is the treatment of choice. The use of corticosteroids reduces the duration of the acute phase, but does not affect long-term prognosis. Inhaled corticosteroids and bronchodilators may be used when there is evidence of airflow limitation, but there is no evidence basing its use.
- Study hypothesis
The investigators' hypothesis is that a proportion of patients diagnosed with chronic HP exhibit expiratory flow limitation, due to airway obstruction caused mostly by the bronchiolar involvement characteristic of this pathology. This involvement could be quantified through other functional tests, such as FOT, and imaging techniques such as high resolution CT scan of the chest with expiratory scans. This may be one of the mechanisms that justifies the lower exercise capacity and greater degree of dyspnea on exertion in these individuals, together with other factors secondary to interstitial lung fibrosis, even in those patients with normal FEV1 (forced expiratory volume in 1 second) /FVC (forced vital capacity) , FEV1, residual volume (RV) and resistance.
- Conditions
- Hypersensitivity Pneumonitis, Airway Disease Small
- Being tested
- Salbutamol
- Medical subject headings
- Alveolitis, Extrinsic Allergic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SalbutamolDrug
Also called Aerolin
Salbutamol after spirometry, plethysmography and forced oscillation technique.
| Study group | Role | What they receive |
|---|---|---|
| Chronic HP patients | Other | Chronic hypersensitivity pneumonitis patients - use of salbutamol Receives: Drug: Salbutamol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pletismography - forced expiratory volume in 1 second / forced vital capacity (FEV1/FVC) < 0.7, residual volume (VR) and VR/total lung capacity (TLC) values and changes with salbutamol
Percentage of VEF1/FVC < 0.7, residual volume (VR) >120% predicted and VR/total lung capacity (TLC)>.45 values and changes with salbutamol
Measured: One day visit
Secondary outcomes (2)
Air trapping in expiratory chest CT scans
Expiratory / inspiratory mean lung attenuation ratio as a measure of air trapping
Measured: One day visit
Reactance and impedance of small airways through forced oscillation technique
Reactance and impedance of small airways
Measured: One day visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2015 (estimated)
- Study start1 Sep 2015
- Primary completion1 Jun 2017
- Study completion20 Nov 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Hypersensitivity PneumonitisStudies of the same condition, open and under way.
- More trials run by University of Sao Paulo General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Olívia Meira Dias, University of Sao Paulo General Hospital
- Investigators
- Carlos Roberto R de Carvalho, MD, PhD, Principal investigator, Heart Institute (InCor)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02523833
- Sponsor's protocol ID
- SDC 3966/13/091
- Status last verified
- May 2018
- First submitted
- 9 Aug 2015
- Last updated
- 2 May 2018
- Results posted
- No
- Data monitoring committee
- No
Publications
Dellaca RL, Duffy N, Pompilio PP, Aliverti A, Koulouris NG, Pedotti A, Calverley PM. Expiratory flow limitation detected by forced oscillation and negative expiratory pressure. Eur Respir J. 2007 Feb;29(2):363-74. doi: 10.1183/09031936.00038006. Epub 2006 Nov 1.
PubMed 17079262Dellaca RL, Santus P, Aliverti A, Stevenson N, Centanni S, Macklem PT, Pedotti A, Calverley PM. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J. 2004 Feb;23(2):232-40. doi: 10.1183/09031936.04.00046804.
PubMed 14979497Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M, Cormier Y; HP Study Group. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003 Oct 15;168(8):952-8. doi: 10.1164/rccm.200301-137OC. Epub 2003 Jul 3.
PubMed 12842854Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, Aziz N, Kaminski N, Zlotnik A. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006 Jan 15;173(2):188-98. doi: 10.1164/rccm.200504-644OC. Epub 2005 Sep 15.
PubMed 16166619Lynch DA, Newell JD, Logan PM, King TE Jr, Muller NL. Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR Am J Roentgenol. 1995 Oct;165(4):807-11. doi: 10.2214/ajr.165.4.7676971.
PubMed 7676971Silva CI, Muller NL, Lynch DA, Curran-Everett D, Brown KK, Lee KS, Chung MP, Churg A. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology. 2008 Jan;246(1):288-97. doi: 10.1148/radiol.2453061881.
PubMed 18096541Buschman DL, Gamsu G, Waldron JA Jr, Klein JS, King TE Jr. Chronic hypersensitivity pneumonitis: use of CT in diagnosis. AJR Am J Roentgenol. 1992 Nov;159(5):957-60. doi: 10.2214/ajr.159.5.1414806.
PubMed 1414806
Study at a glance
From the registry record, last updated by the sponsor on 2 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis and Its Impact on Exercise Limitation
- ClinicalTrials.gov ID
- NCT02523833
- Acronym / sponsor ID
- SDC 3966/13/091
- Conditions
- Hypersensitivity Pneumonitis, Airway Disease Small
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- University of Sao Paulo General HospitalUniversity, hospital or other
- Study start
- 1 Sep 2015 (actual)
- Primary completion
- 1 Jun 2017 (actual)
- Study completion
- 20 Nov 2017 (actual)
- First posted
- 14 Aug 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hypersensitivity pneumonitis (HP) is a syndrome with variable clinical presentation in which lung inflammation is caused by inhalation of specific organic antigens or low molecular weight particles in previously sensitized individuals. Systemic symptoms may or may not be present. Chronic HP represents the final stage of the disease, caused by prolonged exposure to a particular antigen, leading to pulmonary fibrosis. In chronic HP, pulmonary function tests (PFTs) commonly present a restrictive ventilatory pattern, with decreased diffusion of carbon monoxide (DLCO). Some patients can also have obstructive disorders with expiratory flow limitation, due to obstruction of the small airways typically caused by bronchiolar involvement in this pathology. However, PFTs are relatively insensitive for detecting small airway involvement when there is concomitant interstitial fibrosis. First, conventional PFTs may be normal in patients with small airway involvement, since they contribute to less than 30% of the total airway resistance. In addition, damage to the small airways in HP is generally occurring parallel to areas of focal fibrosis - even when small airways are involved, these regions can be completely ignored, since they are excluded from ventilation. In summary, traditional PFTs are not sufficiently sensitive to detect diffuse small airway involvement in these diseases. In these cases, other functional tests, such as forced oscillation technique (FOT) and high resolution computer tomography (HRCT) scans of the chest with expired studies, could be used for this purpose.
This will be a cross-sectional study, which will include the following evaluations in 28 patients with HP recruited from our clinic:
- Clinical variables: (A) demographic and anthropometric data; (B) Clinical data: Onset of symptoms and time of diagnosis
- Dyspnea score:
- Smoking: * Current or former smoker * Smoking history (number of cigarettes smoked per day and for how long);
- Spirometry with forced and slow maneuvers before and after bronchodilator (salbutamol);
- Plethysmography to measure lung volumes;
- Diffusion capacity of carbon monoxide (DLCO);
- High-resolution chest CT with expiratory scans;
- Six-minute walk test;
- Cardio-respiratory test using a maximal incremental treadmill.
- Forced oscillation technique (FOT).
Detailed description
Hypersensitivity pneumonitis (HP) is a syndrome with variable clinical presentation, in which inflammation in lung parenchyma is caused by inhalation of organic antigens or specific low molecular weight substances in previously sensitized individuals. Systemic symptoms may or not be present. Chronic HP represents the final stage of this disease, where prolonged exposure to a particular antigen would lead to lung fibrosis. The list of new antigens is growing, but the main antigens responsible for this disease are exposure to mold and birds.
Not all exposed individuals develop HP. The pathophysiology involves initial exposure and a subsequent decrease in antigen tolerance. Genetic susceptibility can also modulate the immune response to a specific antigen.
There are no reliable epidemiological data on the incidence or prevalence of HP. Differences in the type of antigen sensitization, lack of standardized diagnostic criteria and underreporting are possible factors. In Mexico, one of the few population surveys showed an estimated incidence of 30 cases per 100000 inhabitants in 2 years (1988-1990); however, there are some bias that limit the extrapolation of data to other contexts.
The patient rarely associates the onset of symptoms with a relevant exposure, making it important to actively search for environmental factors against respiratory complaints. It is believed that intermittent exposure to an antigen, long-term exposure to a small load of antigen or a cumulative effect of multiple episodes of acute exposure can cause chronic HP. It is noteworthy that only a small proportion of patients with a single episode of acute exposure will develop chronic HP.
In chronic HP, the patient complains of dyspnea on exertion and dry cough. Systemic symptoms such as fever and weight loss are rarely reported and may be associated with episodes of acute exposure. Physical examination reveals crackles and less commonly, digital clubbing. Auscultation may reveal the presence of squawks arising from the abrupt opening of small airways. Hypoxemia is found in patients with more severe lung disease.
The differential diagnosis with other fibrosing interstitial diseases is challenging, due to the overlap of clinical history, functional and tomographic findings in the terminal stages of these pathologies. There is no gold standard test for diagnosis of HP in all its forms: the diagnosis results in the combination of epidemiological, clinical, radiological data and other exams.
High resolution computer tomography (HRCT) has a fundamental role in the differential diagnosis. However, in advanced stages, the tomographic scans can demonstrate a pattern indistinguishable from nonspecific interstitial pneumonia (NSIP) or usual interstitial pneumonia (UIP), with presence of architectural distortion, traction bronchiectasis and bronchiolectasis, minimum ground glass opacities and honeycombing. The interpretation of HRCT allows "clues" for the differential diagnosis with other idiopathic intersticial pneumonias (IIPs). In comparative HRCT studies, there were some findings showing small airway involvement, such as lobular areas with decreased attenuation and vascularity, air trapping and ground glass or centrilobular micronodules Surgical biopsy may aid in the differential diagnosis of HP from other chronic idiopathic interstitial pneumonitis, especially when exposure is unclear. Even in advanced fibrosis, the accentuation of inflammation around the small airways is the major finding.
Pulmonary function tests (PFTs) commonly show restrictive ventilatory defect with decreased DLCO. There may be concomitant obstructive ventilatory defect, secondary to involvement of the small airways.
However, PFTs are relatively insensitive for detecting small airway involvement when there is concomitant interstitial fibrosis. Firstly, conventional PFTs may be normal in patients with involvement of small airways since they contribute to less than 30% of total airway resistance. Furthermore, damage to small airways in HP is generally focal occurring in parallel with fibrosed areas - even when small airways are involved, these regions may be completely disregarded since they are excluded from ventilation, with PFTs globally featuring a standard restrictive pattern.
In summary, traditional PFTs are not sensitive enough to detect diffuse small airway involvement in these diseases, no matter how severe it is, neither can detect focal changes. In these cases, the investigators hypothesize that other tests, such as forced oscillometry technique (FOT), with its experience widely recognized in the context of evaluation of obstructive diseases like asthma and chronic obstructive pulmonary disease (COPD) and the technique of negative expiratory pressure (NEP) could be used for this purpose. For now, imaging tests, especially high-resolution tomography with expiratory scans, seem to be more sensitive to detect small airway involvement.
Removal of the causal exposure is the treatment of choice. The use of corticosteroids reduces the duration of the acute phase, but does not affect long-term prognosis. Inhaled corticosteroids and bronchodilators may be used when there is evidence of airflow limitation, but there is no evidence basing its use.
- Study hypothesis
The investigators' hypothesis is that a proportion of patients diagnosed with chronic HP exhibit expiratory flow limitation, due to airway obstruction caused mostly by the bronchiolar involvement characteristic of this pathology. This involvement could be quantified through other functional tests, such as FOT, and imaging techniques such as high resolution CT scan of the chest with expiratory scans. This may be one of the mechanisms that justifies the lower exercise capacity and greater degree of dyspnea on exertion in these individuals, together with other factors secondary to interstitial lung fibrosis, even in those patients with normal FEV1 (forced expiratory volume in 1 second) /FVC (forced vital capacity) , FEV1, residual volume (RV) and resistance.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Chronic HP patients | Other | Drug: SalbutamolChronic hypersensitivity pneumonitis patients - use of salbutamol |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Diagnosis of chronic hypersensitivity pneumonitis confirmed by:
- Age between 18 to 75 years;
- Clinically stable (no exacerbations or hospitalizations related to the underlying disease) for at least 6 weeks;
- Compliance with signing an informed consent for participation in the project.
Key exclusion criteria (8 listed)
- Patients with FEV1 and / or DLCO <30% predicted;
- Patients using supplemental oxygen;
- Previous diagnosis of asthma or COPD;
- Pregnant women;
- Musculoskeletal disorders that limit exercise;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SalbutamolAlso: AerolinSalbutamol after spirometry, plethysmography and forced oscillation technique. | Drug | Chronic HP patients |
Primary outcome
Pletismography - forced expiratory volume in 1 second / forced vital capacity (FEV1/FVC) < 0.7, residual volume (VR) and VR/total lung capacity (TLC) values and changes with salbutamol
Time frame: One day visit
Percentage of VEF1/FVC < 0.7, residual volume (VR) >120% predicted and VR/total lung capacity (TLC)>.45 values and changes with salbutamol
2 secondary outcomes
Air trapping in expiratory chest CT scans
Time frame: One day visit
Reactance and impedance of small airways through forced oscillation technique
Time frame: One day visit
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 May 2018.
- Background: PubMed 17079262Dellaca RL, Duffy N, Pompilio PP, Aliverti A, Koulouris NG, Pedotti A, Calverley PM. Expiratory flow limitation detected by forced oscillation and negative expiratory pressure. Eur Respir J. 2007 Feb;29(2):363-74. doi: 10.1183/09031936.00038006. Epub 2006 Nov 1.
- Background: PubMed 14979497Dellaca RL, Santus P, Aliverti A, Stevenson N, Centanni S, Macklem PT, Pedotti A, Calverley PM. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J. 2004 Feb;23(2):232-40. doi: 10.1183/09031936.04.00046804.
- Results publication: PubMed 12842854Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, Erkinjuntti-Pekkanen R, Muller N, Colby TV, Schuyler M, Cormier Y; HP Study Group. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003 Oct 15;168(8):952-8. doi: 10.1164/rccm.200301-137OC. Epub 2003 Jul 3.
- Results publication: PubMed 16166619Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, Aziz N, Kaminski N, Zlotnik A. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006 Jan 15;173(2):188-98. doi: 10.1164/rccm.200504-644OC. Epub 2005 Sep 15.
- Results publication: PubMed 7676971Lynch DA, Newell JD, Logan PM, King TE Jr, Muller NL. Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR Am J Roentgenol. 1995 Oct;165(4):807-11. doi: 10.2214/ajr.165.4.7676971.
- Results publication: PubMed 18096541Silva CI, Muller NL, Lynch DA, Curran-Everett D, Brown KK, Lee KS, Chung MP, Churg A. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology. 2008 Jan;246(1):288-97. doi: 10.1148/radiol.2453061881.
- Results publication: PubMed 1414806Buschman DL, Gamsu G, Waldron JA Jr, Klein JS, King TE Jr. Chronic hypersensitivity pneumonitis: use of CT in diagnosis. AJR Am J Roentgenol. 1992 Nov;159(5):957-60. doi: 10.2214/ajr.159.5.1414806.
Related trials for Hypersensitivity Pneumonitis
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Recruiting
Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis
Hypersensitivity Pneumonitis
RecruitingObservational study
Contribution of the Indoor Environment Medical Advisor in the Management of Fibrosing Hypersensitivity Pneumonitis
Hypersensitivity Pneumonitis
Not yet recruitingPhase 4
Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD
Interstitial Lung Disease
Active, not recruitingEarly Phase 1
FAPI PET for Lung Fibrosis
Interstitial Lung Disease, Idiopathic Interstitial Pneumonias
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carlos Roberto R de Carvalho, MD, PhD principal investigator
Heart Institute (InCor)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Salbutamol in people with Hypersensitivity Pneumonitis and Airway Disease Small, run by University of Sao Paulo General Hospital at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 May 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pletismography - forced expiratory volume in 1 second / forced vital capacity (FEV1/FVC) < 0.7, residual volume (VR) and VR/total lung capacity (TLC) values and changes with salbutamol (time frame: One day visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02523833, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2018.